Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02221726 · ClinicalTrials.gov registry record · Early Phase 1
Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults
A Early Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT02221726: Completed Early Phase 1 study, sponsored by Janssen Research & Development.
NCT02221726 is a Early Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 16 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02221726, a Early Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to assess 3 different scoring systems to evaluate the adhesive quality of placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial\]) JNJ-35685-AAA-G-023-G transdermal (through the skin) systems during a single system 72-hour application, replicated 3 times, of 2 patch sizes (5.5 centimeter\^2 \[cm\^2\] and 44 cm\^2).
Primary Outcome
Visual grading US FDA scale will be used to evaluate adhesion performance of the transdermal system. The score ranges from 0-4: 0 = greater than or equal to (\>=) 90 percent (%) adhered (essentially no lift off the skin); 1 = greater than or equal to 75% to less than (\<) 90% adhered (some edges only lifting off the skin); 2 = greater than or equal to 50% to \<75% adhered (less than half of the patch lifting off the skin); 3 = greater than (\>) 0% to \<50% adhered but not detached (more than hal
Interventions
- DRUG JNJ-35684-AAA-023: Size 1; small patch
- DRUG JNJ-35684-AAA-023: Size 2; large patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-08 |
| Phase | Early Phase 1 |
What the finished NCT02221726 record still lists
NCT02221726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 2 interventions - of which JNJ-35684-AAA-023: Size 1; small patch is the first listed.
NCT02221726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02221726 about?
NCT02221726 is a clinical study titled "Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults". The purpose of this study is to assess 3 different scoring systems to evaluate the adhesive quality of placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial\]) JNJ-35685-AAA-G-023-G transdermal (through the skin) systems during a s...
What is the current status of trial NCT02221726?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2014-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02221726?
The interventions under investigation include: JNJ-35684-AAA-023: Size 1; small patch (DRUG), JNJ-35684-AAA-023: Size 2; large patch (DRUG).
Who is sponsoring clinical trial NCT02221726?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02221726's enrollment target sits among peer trials
16 1369th of 2000 higher than 598 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia